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and in the a b s t r a c t
n today’s healthcare paradigm, optimal sedation during anesthesia plays an important role both in patient welfare Today’s socio-economic context puts a lot of pressure on the standard practices and guidelines in intensive care unocio-economic context. For the closed-loop control of general anesthesia, two drugs have proven to have stable, rapid onset 
imes: propofol and remifentanil. These drugs are related to their effect in the bispectral index, a measure of EEG signal. In this 
aper wavelet time–frequency analysis is used to extract useful infor-mation from the clinical signals, since they are time-varying 
nd mark important changes in patient’s response to drug dose. Model based predictive control algorithms are employed to 
egulate the depth of sedation by manipulating these two drugs. The results of identiﬁ-cation from real data and the simulation of 
he closed loop control performance suggest that the proposed approach can bring an improvement of 9% in overall robustness 
nd may be suitable for clinical practice.Keywords:
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1. Introductionit and 
operation theater. Stringent regulations concerning patient safety and welfare have motivated anesthesiologists to allow 
more and more the use of closed loop control within the clinical practice [1]. From the latest advances in closed loop control 
of depth of anesthesia, it became clear that a patient-individualized model for drug effect predictions is crucial in ensuring 
optimal performance within the imposed constraints [2].
The earliest controllers developed for general anesthesia are of the Proportional-Integrative-Derivative (PID) type [3]. Due 
to the fact that PID controllers cannot anticipate to the response of the patient and have limited robustness, stability prob-
lems may arise. Therefore, strategies using model based predictive control (MPC) [4] and Bayesian-based control algorithms 
[5,6] have been suggested and successfully applied in practice. The current bottleneck is the speciﬁc characterization of the 
multiple drug input and its synergistic effect upon the depth of anesthesia for personalized healthcare.
In general, biological signals and systems are non-stationary and contain time delays [7,8]. The efﬁciency of wavelet tools
employed to extract useful information for anesthesia has been shown in several recent works [9]. In this paper, we employ
clinically available signals from intensive care unit clinical trials executed at the Ghent University Hospital, Belgium. The sig-
nals are recorded from patients under general anesthesia during their stay at the intensive care unit and are the result of
manual control, i.e. of a specialized clinical nurse who is keeping the patient’s vital signs stable.
It has been shown that these two drugs, i.e. propofol and remifentanil, have synergic effects on hypnosis level and can be
administrated together for a suitable depth of anesthesia regulation. The pharmacodynamic relation between the drug con-
centrations in the body and their effect can be characterized by a nonlinear surface known as the Sigmoid Hill curve. Since
this surface is nonlinear with respect to the variations in the drug concentrations in blood, it is difﬁcult to perform identi-
ﬁcation and the global solution is not always feasible due to safety constraints. During their stay at the intensive care unit,
the anesthestized patient is maintained within a speciﬁc interval of the electrical activity in the brain, measured by electro-
encephalogram (EEG). Since the EEG is rather noisy and complex, several data channels are combined by means of signal
processing techniques and a singular value is delivered, between 0–100%, i.e. isoline EEG and fully awake patient respec-
tively. This singular value is known as the dimensionless Bispectral Index (BIS) and sensors are commercially available
for the clinical practice. The exact details of the algorithm used to create the BIS index have not been disclosed by the com-
pany that developed it (Aspect Medical Systems). By having this measure at hand, a linear model can be approximation, since
the nonlinear surface is piecewise linear. The results of such a linear identiﬁcation procedure are presented in this work,
along with an evaluation of closed loop control. Several simulations are performed, which demonstrate that the inter-patient
variability is tackled successfully by means of this personalized closed loop predictive control algorithm.
Having these ideas in mind, the paper is structured as follows. Section 2 presents the clinical data used for identiﬁcation,
the modeling approach to describe drug interaction, the signals ﬁltering and the MPC strategy. Section 3 develops the iden-
tiﬁcation and the control algorithms. The results obtained are discussed in detail in Section 4. A conclusion section summa-
rizes the main outcome of this paper.
2. Materials and methods
2.1. Clinical data
The data used for the identiﬁcation purpose in this paper is a selection of a larger study ongoing at Ghent University Hos-
pital, where clinical trials have been performed during the period September 2007–May 2010. Written informed consent was
obtained from the patient or legal representative. The study protocol was approved by the local Ethics Committee of Ghent
University Hospital, and was performed in accordance with the Declaration of Helsinki and the Good Clinical Practice Guide-
line of the European Commission. Patients were routinely regarded eligible for inclusion according to the following criteria:
i) patients in the immediate post-operative phase after a coronary artery bypass graft (CABG) surgery and ii) age higher than
18 years.
Data from 5 patients receiving manually controlled propofol and remifentanil sedation was selected for this study. An
existing and previously validated software platform was used to record the data and to control the syringe pumps delivering
the drugs to these patients, i.e. RUGLOOP II, Demed, Temse, BELGIUM [10]. Target-controlled infusion technology available in
RUGLOOP II was applied during drug delivery. Measurements were performed every second, using the standard Aspect Med-
ical Brain Monitoring System, which delivers the BIS signal values to a clinical interface. The BIS was acquired using standard
3–4 electrode sensors, adjustable on adult head frontal The biometric values of the patients selected for this study are given
in Table 1.
The clinical trials have been performed during 6 h. In most of the patients, after the ﬁrst hour, the peri-operative drugs are
not active anymore and the patient is less deeply sedated.
2.2. Patient model
The most commonly used drugs for anesthesia in Belgium are propofol and remifentanil. They have a reliable pharmaco-
logical proﬁle, with fast onset and recovery times, making them suitable candidates for closed loop control of depth of
anesthesia.Table 1
Biometric values of the patients selected for this study; BMI: body mass index.
Patient Age (years) Length (cm) Weight (kg) Gender BMI
1 53 186 114 M 32
2 71 172 83 M 28
3 72 162 87 M 33
4 61 182 93 M 28
5 69 158 81 M 32
Mean  Std 62.5  9.5 172  14 97.5  16.5 – 30.6  2.4
Propofol is a hypnotic agent, whose pharmacological properties have been well described and studied in different kind of
patients [11,12]. Remifentanil is an opioid with a unique pharmacological proﬁle, best characterized by its high metabolic
clearance, independent of the most common metabolic pathways which are usually known to metabolize anesthetic drugs
[13,14]. When administered together, these two drugs interact synergistically on both hypnotic and analgesic components of
sedation. Their combined effect is characterized by the BIS, a signal derived from the electroencephalogram (EEG) [15]. Using
EEG, several derived, computerised parameters like the BIS have been tested and validated as a promising measure of the
hypnotic component of anesthesia [21]. BIS combines several features extracted from EEG including higher order spectra
of the signal which can reveal phase coupling of single waveforms. Multivariate statistics were used to combine the different
features into a single indicator value [22]. BIS values are given in units of percentage of hypnosis and lie in the range of
0–100%; whereas 90–100% range represents fully awake patients, 60–70% range indicate light hypnosis and 40–60% range
indicate moderate hypnotic state. For patient safety and fast recovery time, BIS should not decrease during clinical interven-
tions below 30% and should not increase above 70%.
Some artifacts may be present in the measured BIS signal, e.g. due to body movement, eye movements, coughing, sweat-
ing, etc. A typical BIS signal with body movement and coughing artefacts is presented in Fig. 1. The task of the anesthesiol-
ogist is to prevent those high amplitude values by injecting the appropriate drug dose. This is a complex task, due to the
intra- and inter-patient variability and automatic control of general anesthesia is a challenging demand.
Pharmaco-kinetic and pharmaco-dynamic (PK-PD) blocks denote compartmental models. The PK-PD models most com-
monly used for propofol and remifentanil are the 4th order compartmental model depicted in Fig. 2.
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7775  u: ð1Þwhere x1 [mg] denotes the amount of drug in the central compartment. The blood concentration can be expressed by x1=V1,
where V1 is the volume of blood in the central compartment. The peripheral compartments 2 and 3 model the drug exchange
of the blood with well (i.e. muscles) and poorly (i.e. fat) diffused body tissues. The masses of drug in fast and slow equili-
brating peripheral compartments are denoted by x2 and x3, respectively. The parameters kji, for i – j, denote the drug transfer
frequency from the jth to the ith compartment and uðtÞ [mg/s] is the infusion rate of the drug into the central compartment.
The additional hypothetical effect compartment represents the lag between drug plasma concentration and drug
response. The amount of drug in this compartment is represented by Ce. The parameters kij of the PK models depend on
age, weight, height and gender and the relations can be found for propofol in [11,12] and for remifentanil in [13,14]. This
hypothetical effect compartment makes the link to the drug effect, i.e. BIS values, by a sigmoid nonlinear, time-varying curve
as represented in Fig. 3. This is also the nonlinear drug/effect relation block from Fig. 2. The typical sigmoid shape relating the
BIS values to the effect site concentration Ce, starts with a ﬂat plateau. During this time no closed loop feedback control can
be applied since there is no useful feedback signal available the Propofol drug is infused into the patient while BIS values do
not vary signiﬁcantly; moreover, in practice the little variation is hidden in noise. In practice, during this time, manual con-
trol is applied until BIS values show a certain variation DBIS. If the desired BIS value is BIS = 50%, then the concentrationFig. 1. Real BIS signal where artifacts can be observed. First artefact is coughing and the other three are due to body movement.
Fig. 2. General compartmental model of the patient, where PK denotes the pharmacokinetic model and PD denotes the pharmacodynamic model of an
infused drug.
Fig. 3. Sigmoid curve of the effect from one drug. TCI stands for target controlled infusion, the standard practice in clinical trials (i.e. open loop control).needed to be achieved in the blood of the patient is denoted by C50. This values is usually some averaged value over a large
population database and can be adopted as a starting point of adaptation of the patient speciﬁc model.
When considering the effect of two drugs, the nonlinear drug/effect relation, represented by the block from Fig. 2 is in fact
a 3D function, leading to a nonlinear surface representing the synergistic effect of both propofol and remifentanil drugs.
The nonlinear complex synergy of the two drugs can be described by a normalized, time-varying relation [15]:BISðtÞ ¼ E0  EmaxðhÞ 
UPropðtÞþURemðtÞ
U50ðhÞ
 cðhÞ
1þ UPropðtÞþURemðtÞU50ðhÞ
 cðhÞ ; ð2ÞFig. 4. Block diagram of the patient model for two drug inputs and one output effect.
Fig. 5. Sigmoid surface of the effect from two drugs.where: UPropðtÞ þ URemðtÞ is the combined drug concentration; cðhÞ is the steepness of the concentration–response relation at
ratio h;U50ðhÞ is the number of drug units associated with 50% of maximum effect at ratio h; EmaxðhÞ is the maximum possible
drug effect at ratio h. The effect-site concentrations CeProp and CeRem are normalized to their respective potencies C50Prop and
C50Rem as described by:UPropðtÞ ¼ CePropðtÞC50Prop ;URemðtÞ ¼
CeRemðtÞ
C50Rem
; ð3Þand the time-varying ratio of the interacting drugs is expressed by:hðtÞ ¼ UPropðtÞ
UProp þ URem ; ð4ÞIn this formulation, h represents the concentration ratio of the new combined drug and ranges from 0 (Remifentanil only) to
1 (Propofol only). The values for EmaxðhÞ and E0 are usually set to 100% and U50ðhÞ can be expressed by a quadratic polynomial:U50ðhÞ ¼ 1 b  hþ b  h2: ð5Þ
The unknown parameter b is usually estimated from the patient data. Since the interaction between the two drugs is supra-
additive (the effect of the two drugs combined is higher than the sum of each separate effect), then b > 0. This means that
U50ðhÞ < 1 for 0 < h < 1. However, in the application presented in this paper, this model is applied to patients in intensive
care unit, i.e. BIS should be maintained within an interval of [40–60%]. Consequently, the highly nonlinear surface from
(2) can be approximated just by a linear function:BISðtÞ ¼ m1  CePropðt  sdÞ þm2  CeRemðt  sdÞ þ b; ð6Þ
where m1 and m2 are the slopes, b is a constant and sd is the time delay introduced by the signal processing of the BIS mon-
itor [16].
2.3. Wavelet transformation and identiﬁcation
During general anesthesia, the patient’s response to the infused drug is varying considerably. This results in non-station-
ary signals which change their power spectral density function in time. Since all models used for prediction of drug infusion
rates are based on a general population dataset, it is obvious that they will no longer correspond to the actual dynamics of
each particular patient. Hence, it is necessary to obtain suitable models that can be easily adapted online to the intra-patient
variability and avoid over- and under-sedation.
In order to analyze a non-stationary signal in time–frequency domain, wavelet analysis can be employed, by multiplying
the non-stationary signal xðtÞ by a function [17]. Considering the mother wavelet function w centered at time instant s and
scaled by a factor s, the continuous wavelet transform (CWT) of the signal xðtÞ is represented by [18]:CWTðs; sÞ ¼ 1ﬃﬃﬃﬃﬃjsjp
Z þ1
1
xðtÞ  w t  s
s
 
dt: ð7Þ
The digital version of the CWT is the discrete wavelet transform (DWT). A way to implement the DWT using ﬁlters was
developed by Mallat [18]. Filters of different cut-off frequencies are used to separate the signal. The concept is schematically
illustrated in Fig. 6, where gi denote low-pass ﬁltering and hi denote high-pass ﬁltering. Speciﬁc details are given in the
‘Results’ section.
At the ﬁrst level, the signal is decomposed simultaneously using a low pass and high pass ﬁlter. This procedure is repeated
and the approximation coefﬁcients are decomposed again with high and low pass ﬁlters. There are several wavelet families
proposed by different researchers. The wavelet used in this study is the Haar function, due to its small computational time,
represented by the following formula:wðtÞ ¼
1 0 6 t < 12
1 12 6 t < 1
0 otherwise:
8><
>: ð8ÞFor the application in this study, we were interested to capture the intra-patient variability from the ﬁltered BIS signal.
Therefore, the total length of the BIS signal was divided in several windows and identiﬁcation applied on each data interval,
as detailed in the ‘Results’ section. The unknown parameters of the linear approximation (6), namely m1; m2 and b were
identiﬁed using the classical least-squares method. The time-delay sd was estimated based on cross-correlation analysis
[16].2.4. MPC-EPSAC strategy
The inherent capability of MPC to outperform other control strategies has been already shown in [19,4] by means of sim-
ulations evaluating both the performance and the robustness of the closed loop system. In the general MPC scheme repre-
sented in Fig. 7, the patient model is used to predict the future value of the output variable B^IS. The difference between the
measured BIS from the patient and the model output (residual), serves as feedback signal in the prediction block. With this
residual and the input u, the prediction block predicts the future values of the output B^IS. On the basis of these predicted B^IS
values, the controller calculates the future optimal drug infusion rates over a number of samples in the future, called the
prediction horizon and denoted by N2 samples. However, only the ﬁrst calculated sample value is applied to the process
(i.e. principle of receding horizon). Notice that this algorithm is naturally based on digital control (sampled data).
In this paper, the EPSAC (Extended Prediction Self-Adaptive Control) strategy is employed [20]. The EPSAC algorithm is
based on a generic process model:BISðtÞ ¼ B^ISðtÞ þ nðtÞ; ð9Þwith t denoting time instants. The term nðtÞ includes the effects in the measured output BISðtÞ which do not come from the
model input uðtÞ via the available model output B^ISðtÞ. The information carried by this term is a combination of twofold ori-
gins: i) modeling errors and ii) physical disturbances on the measured signal coming from the measurement equipment,Fig. 6. A diagram of the steps performed within the wavelet ﬁltering algorithm.
Fig. 7. MPC scheme for closed loop BIS regulation. Notice that this differs from the standard PID control scheme, since the MPC is an advanced control
algorithm which requires the availability of a model for prediction, i.e. the controller receives two variables: target BIS and predicted BIS.movement of the patient, etc. However, these effects have a stochastic character with non-zero average value, which can be
modeled by a colored noise process:nðtÞ ¼ C
D
 eðtÞ; ð10Þwhere eðtÞ – uncorrelated (white) noise with zero mean value; C and D – monic polynomials of orders nc and nd. Commonly,
the disturbance ﬁlter (10) is deﬁned as a pure integrator, to ensure zero steady state error. The relationship between uðtÞ and
B^ISðtÞ is given by generic dynamic system models. In our case the input applied to the patient, ½u1 u2, is a vector containing
the Propofol and Remifentanil delivery rates. The prediction model is represented by (1) and (6). The process output is pre-
dicted at time instant t over the prediction horizon N2, based on the measurements available at that moment and the future
outputs of the control signal, as schematically represented in Fig. 8. The values of the output predicted at the time instant t
over k samples in the future are denoted by ðt þ kjtÞ and deﬁned as:BISðt þ kjtÞ ¼ B^ISðt þ kjtÞ þ nðt þ kjtÞ: ð11Þ
Prediction of B^ISðt þ kjtÞ and of nðt þ kjtÞ can be done respectively by recursion of the process model and by using ﬁltering
techniques on the noise model (10). The controller output is obtained by minimizing:JðUÞ ¼
XN2
k¼N1
BISðt þ kjtÞ  B^ISðt þ kjtÞ
h i2
; ð12Þwhere BISðt þ kjtÞ is the desired reference trajectory, BIS is the target BIS value and N1 is the number of samples corre-
sponding to the time delay (the prediction is calculated after the time delay). This cost function is a quadratic form in U, hav-
ing the following structure:Fig. 8. A diagram of the concept of prediction in MPC; u denotes the input, y denotes the output.
JðUÞ ¼ ðBIS  BIS G  UÞT :ðBIS  BIS G  UÞ; ð13Þ
where BIS is the predicted output of the response of the process model calculated if the postulated input would be kept con-
stant at its value applied at time ðt  1Þ. The postulated input is a choice that the user makes in the design of the controller
and it corresponds to the simplest case, namely when the control horizon Nu ¼ 1 sample. Of course, the control horizon can
take other values, but this only increases numerical complexity of the algorithm (i.e. matrix size) without signiﬁcant perfor-
mance improvement. For the speciﬁc case if control horizon of 1 sample, the G matrix is represented by:G ¼
m1  gPropN1 m2  gRemN1
. . . . . .
m1  gPropN2 m2  gRemN2
2
64
3
75; ð14Þwhere gPropN1 . . . gPropN2 and gRemN1 . . . gRemN2 are the coefﬁcients of the unit step response of the PK-PD propofol model
and PK-PD remifentanil model, respectively. Minimization w.r.t. U leads to the optimal solution:U ¼ GT  G
h i1
 GT  BIS  BIS
 
: ð15ÞOnly the ﬁrst element in U is required in order to compute the actual control input applied to the process:uðtÞ ¼ ubaseðtjtÞ þ Uð1Þ; ð16Þ
where the notation ðtjtÞ denotes the prediction made at time instant t and given that ubase are past predicted inputs to the
process. At the next sampling instant t þ 1, the whole procedure is repeated taking into account the newmeasurement infor-
mation BISðt þ 1Þ.
The MPC-EPSAC strategy was implemented to control the level of BIS, using the model presented in Fig. 4. Since we have
two inputs and one output, when using the default cost function (12) we obtain an inﬁnite number of solutions. The cost
function can be extended in order to penalize the control movements and in this way the search region is restricted, leading
to a unique solution:JðUÞ ¼
XN2
k¼N1
½BISðt þ kjtÞ  B^ISðt þ kjtÞ2 þ k1
XN21
k¼0
½UPropðt þ kjtÞ2 þ k2
XN21
k¼0
½URemðt þ kjtÞ2; ð17Þwhere k1 and k2 are weighting parameters.
3. Results
3.1. Filtering the real BIS signal
The wavelet transform algorithm was used to recover the BIS signal from the noisy recorded data. The BIS signal was
decomposed in different frequency bands, ﬁltered and reconstructed, using the MatLab Wavelet toolbox. Five levels were
adopted for decomposition, shown in Fig. 9, and applied on the BIS signals which vary in the time–frequency locus, as illus-
trated in Fig. 10 for one patient. The choice of the particular values in the decomposition levels is based on the dynamic
response of the patient to drug infusion and to (surgical) stimuli. For instance, the threshold of 0.0031 Hz corresponds to
a time interval of 300 s. A typical surgical stimuli can increase BIS to dangerous values as fast as 30–130 s, thus the lowest
decomposition level we have employed was of the order of 0.0015 Hz.
3.2. Identiﬁcation from real data
In order to identify the parameters online, an algorithm which selects the windows automatically was implemented. This
algorithm has a better performance than the previous one since it takes into account the relation between the parameters
(jm1j > jm2j) and checks the values obtained during several iterations. Negative values were expected to be obtained for m1
and m2, since the relation between the effect site concentrations and BIS is inverse proportional.
The algorithm can be described as follows: The identiﬁcation is initially performed on a window of 20 samples and then
the window is increased with 10 samples. In case the identiﬁed parameters did not reach the upper limit of 0:1 (since both
parameters should have negative values), the algorithm checks if the variation of the parameters is higher than a threshold of
0.5 (to avoid dithering) and if jm1j > jm2j. If these both conditions are fulﬁlled, the values of the parameters are recorded, and
the whole procedure is repeated on a new window of 20 samples. In case the parameters reached the limits, the previous
values of the parameters are used, and the algorithm re-iterated on the same window enlarged with 10 samples.
As an example, the result of the identiﬁcation procedure applied on the data measured from patient #1 is given in Fig. 11.
One may observe the variations in the estimated parameter values, suggesting that these parameters are indeed time-
varying.
The validation against real data is presented in Fig. 12. When the ﬁrst disturbance appears in patient’s dynamics, after the
ﬁrst hour during their stay in the intensive care unit, the URem and UProp rates start to increase. This suggest that the patient is
Fig. 9. Wavelet decomposition tree for ﬁltering the noisy BIS signal.
Fig. 10. An example of time–frequency analysis plot (top) and time signal of BIS (bottom) for one patient.
Fig. 11. Variation in the parameters estimated from data recorded from patient #1.less sensitive to the drug and needs higher infusion rates to maintain the same level of BIS values, visible in the higher values
for m1 and m2. The control performance and the corresponding drug effect is successfully evaluated by the immediate
Fig. 12. Validation of identiﬁed model. Left: the real and estimated BIS signal. Right: the propofol and remifentanil records from patient #1.rejection of the disturbance by adding more drug into the patient and thus resulting in higher values of their blood
concentrations.
The results of the identiﬁcation procedure on the 5 patient records are listed in Table 2. When the patient does not receive
any drug, the BIS is around 90–100%. When they arrive in the intensive care unit, the patients are already sedated from the
operation theater. This explains why the identiﬁed average value of b is already around 50%. Regarding the values obtainedTable 2
Averaged values from estimated model parameter values.
Patient m1 m2 b
1 18.12 13 54.74
2 18.18 10.96 46.37
3 12.12 10.82 36.12
4 11.14 8.04 58
5 12 3.7 63.87
Nominal 14.313.52 9.30  3.59 50.01  13.86
Fig. 13. Controller performance in closed loop under modeling errors and step disturbances. Modeling errors between the simulated patient model and the
averaged patient model used for prediction are taken into account to prove robustness of the controller. Observe the different values of drug in steady state,
showing that the control tackles well the inter-patient variability.
Fig. 14. Blood concentration (Cp) and effect-site concentration (Ce) obtained for different patients.
Table 3
Performance of the closed loop control.
Patient Percentage undershoot Settling time (s) Time elapsed to reject disturbance (s)
1 2.73 120 531
2 1.92 205 545
3 0 144 640
4 0 133 612
5 0 216 702for m1 and m2, one can observe that patient #5 has a higher sensitivity to propofol, compared with the others. Similarly,
patients #2 and #3 have a higher sensitivity to remifentanil.3.3. Closed loop control: a simulation study
The MPC-EPSAC algorithm was simulated using the prediction model from (1) and (6), with averaged values of Table 2.
The optimal design of the controller was obtained for: N1 ¼ 1; Nu ¼ 1; N2 ¼ N1 þ 10 samples, with a sampling period of 10 s.
The following minimal and maximal ﬂow rates were imposed for the propofol and the remifentanil delivery pumps, respec-
tively: 0–3.3 mg/s and 0–3.3 lg/s. The weighting factors from the cost function in (17) were set to k1 ¼ 1000; k2 ¼ 500.
The closed loop control was simulated for different patients, in order to test the inter-patient variability and control
performance for reference changes and disturbance rejection. For simulating each patient in a realistic manner, the corre-
sponding parameters from Table 1 and Table 2 were employed. For prediction, the PK-PD parameters from Table 1 and
the averaged values from Table 2 were employed. The disturbance rejection was evaluated for a step disturbance with
the same amplitude as the one that appears in open-loop in case of patient #1 after one hour. Two disturbances were intro-
duced in the simulation, i.e. at t ¼ 0:1 and t ¼ 0:8 h. The results of the closed loop control simulations are presented in
Fig. 13. It can be observed that the infusion rates are very close to the nominal ones depicted in Fig. 12.
The propofol and remifentanil concentrations estimated from the model for each patient are depicted in Fig. 14. These
concentrations do not go beyond their safety limit of 4.5 of their respective units, as clinically imposed by the standardized
patient safety protocol.
The controller performance for reference tracking and disturbance rejection was also analyzed. The percent of undershoot
and the settling time when the reference is changing with an amplitude of 8% BIS are given in Table 3. The disturbance
rejection time for a step disturbance with the amplitude 25% BIS is given as well. Both these values were chosen based on
typical clinical practice.
From Figs. 13 and 14 we can conclude that patient #5 has the lowest sensitivity to propofol and remifentanil. As a result, a
high quantity of drug is delivered to the patient and a poor performance is obtained for disturbance rejection and reference
tracking. For this patient signiﬁcant modeling errors between the nominal model (used for prediction) and the identiﬁed
model (used for simulating the real patient) occur: 10% error for m1 and 65% for m2. Indeed, the slope given by m2 is more
difﬁcult to estimate due to the indirect effect from Remifentanil drug input to the BIS output value (recall here Fig. 5). There-
fore, it is commendable that the controller has a good performance in closed loop despite such errors in prediction. In con-
trast, the fastest reference tracking is achieved in case of patient #1 at the expense of a small undershoot and this is due to
the high sensitivity to propofol and remifentanil.4. Limitations of this study
A signiﬁcant limitation of this study may be the low number of clinical data from which the model parameters were
derived. However, the proposed model based predictive control strategy has an intrinsic robustness to model variations
and stability has been shown to be guaranteed for signiﬁcant gain variations in [4], i.e. variations between 1:6  k–0:5  k,
with k the gain of the nominal patient model.
The results reported in this study suggest that the control performance has been shown to be more robust by 12% during
induction phase as compared to the study in [4], where only Propofol was administered. The disturbance were not the same
in both studies, so a performance comparison during maintenance is not possible.5. Conclusions
The aim of this study was to present a pragmatic solution for modeling a two-drug synergic effect during general anes-
thesia. The drug interaction and their corresponding effect on the EEG signal was analysed by means of the standardized
measure of depth of sedation, i.e. the bispectral index. A simpliﬁed linear multiple-input single-output model for patient’s
response is proposed. Two PK-PDmodels are used in clinical practice and their parameters are a priori known from biometric
details of the patient: age, weight, gender and height. An interaction model was proposed and, based on the clinical data, the
parameters of this linear model were identiﬁed by means of time–frequency ﬁltering algorithms. The identiﬁed averaged
model proved to sufﬁce for hypnosis level prediction when propofol and remifentanil are administered, with estimated val-
ues very close to those measured in clinical practice. This approach was further supported by the simulation of the closed
loop model based predictive control algorithm, with drug infusion rates and drug concentrations close to clinical practice.Acknowledgment
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